肠道病毒D68抗病毒药物：过去、现在与未来
Enterovirus D68 Antivirals: Past, Present, and Future.
作者信息
Hu Yanmei, Musharrafieh Rami, Zheng Madeleine, Wang Jun
机构信息
Department of Pharmacology and Toxicology, College of Pharmacy, The University of Arizona, Tucson, Arizona 85721, United States.
出版信息
ACS Infect Dis. 2020 Jul 10;6(7):1572-1586. doi: 10.1021/acsinfecdis.0c00120. Epub 2020 May 14.
Abstract
Enterovirus D68 (EV-D68) is an RNA virus that causes respiratory illnesses mainly in children. In severe cases, it can lead to neurological complications such as acute flaccid myelitis (AFM). EV-D68 belongs to the enterovirus genera of the Picornaviridae family, which also includes many other significant human pathogens such as poliovirus, enterovirus A71, and rhinovirus. There are currently no vaccines or antivirals against EV-D68. In this review, we present the current understanding of the link between EV-D68 and AFM, the mechanism of viral replication, and recent progress in developing EV-D68 antivirals by targeting various viral proteins and host factors that are essential for viral replication. The future directions of EV-D68 antiviral drug discovery and the criteria for drugs to reach clinical trials are also discussed.
摘要
肠道病毒D68（EV-D68）是一种主要导致儿童呼吸道疾病的RNA病毒。在严重情况下，它可引发诸如急性弛缓性脊髓炎（AFM）等神经并发症。EV-D68属于小核糖核酸病毒科肠道病毒属，该属还包括许多其他重要的人类病原体，如脊髓灰质炎病毒、肠道病毒A71和鼻病毒。目前尚无针对EV-D68的疫苗或抗病毒药物。在本综述中，我们阐述了目前对EV-D68与AFM之间联系、病毒复制机制的理解，以及通过靶向病毒复制所必需的各种病毒蛋白和宿主因子来开发EV-D68抗病毒药物的最新进展。还讨论了EV-D68抗病毒药物研发的未来方向以及药物进入临床试验的标准。
相似文献
1
Enterovirus D68 Antivirals: Past, Present, and Future.肠道病毒D68抗病毒药物：过去、现在与未来
ACS Infect Dis. 2020 Jul 10;6(7):1572-1586. doi: 10.1021/acsinfecdis.0c00120. Epub 2020 May 14.
2
Pharmacological Characterization of the Mechanism of Action of , a Promising Antiviral for Enterovirus D68.一种有前景的肠道病毒D68抗病毒药物作用机制的药理学特征
ACS Infect Dis. 2020 Aug 14;6(8):2260-2270. doi: 10.1021/acsinfecdis.0c00383. Epub 2020 Aug 5.
3
Genomic Analyses of Acute Flaccid Myelitis Cases among a Cluster in Arizona Provide Further Evidence of Enterovirus D68 Role.对亚利桑那州聚集性急性弛缓性脊髓炎病例的基因组分析提供了更多的肠道病毒 D68 作用证据。
mBio. 2019 Jan 22;10(1):e02262-18. doi: 10.1128/mBio.02262-18.
4
Telaprevir Treatment Reduces Paralysis in a Mouse Model of Enterovirus D68 Acute Flaccid Myelitis.特拉匹韦治疗可减少 D68 肠道病毒急性弛缓性脊髓炎小鼠模型中的瘫痪。
J Virol. 2023 May 31;97(5):e0015623. doi: 10.1128/jvi.00156-23. Epub 2023 May 8.
5
Transcription factor EB (TFEB) interaction with RagC is disrupted during enterovirus D68 infection.转录因子 EB（TFEB）与 RagC 的相互作用在肠道病毒 D68 感染期间被破坏。
J Virol. 2024 Jul 23;98(7):e0055624. doi: 10.1128/jvi.00556-24. Epub 2024 Jun 18.
6
Enterovirus D-68 Molecular Virology, Epidemiology, and Treatment: an Update and Way Forward.肠道病毒 D-68 的分子病毒学、流行病学和治疗：最新进展及未来方向。
Infect Disord Drug Targets. 2021;21(3):320-327. doi: 10.2174/1871526520666200715101230.
7
Neutralizing Antibody Given after Paralysis Onset Reduces the Severity of Paralysis Compared to Nonspecific Antibody-Treated Controls in a Mouse Model of EV-D68-Associated Acute Flaccid Myelitis.在 EV-D68 相关急性弛缓性脊髓炎的小鼠模型中，与非特异性抗体治疗对照组相比，瘫痪发病后给予中和抗体可降低瘫痪严重程度。
Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0022722. doi: 10.1128/aac.00227-22. Epub 2022 Jul 27.
8
Validating Enterovirus D68-2A as an Antiviral Drug Target and the Discovery of Telaprevir as a Potent D68-2A Inhibitor.验证肠道病毒 D68-2A 作为抗病毒药物靶点和发现替拉瑞韦作为有效的 D68-2A 抑制剂。
J Virol. 2019 Mar 21;93(7). doi: 10.1128/JVI.02221-18. Print 2019 Apr 1.
9
Epidemiology of acute flaccid myelitis in children in the Netherlands, 2014 to 2019.荷兰 2014 年至 2019 年儿童急性弛缓性脊髓炎的流行病学。
Euro Surveill. 2022 Oct;27(42). doi: 10.2807/1560-7917.ES.2022.27.42.2200157.
10
A Novel Capsid Binding Inhibitor Displays Potent Antiviral Activity against Enterovirus D68.一种新型衣壳结合抑制剂对肠道病毒D68显示出强大的抗病毒活性。
ACS Infect Dis. 2019 Nov 8;5(11):1952-1962. doi: 10.1021/acsinfecdis.9b00284. Epub 2019 Sep 18.
引用本文的文献
1
Structure-Activity Relationship Studies Towards Analogues of Pleconaril as Novel Enterovirus-D68 Capsid-Targeting Antivirals.作为新型肠道病毒D68衣壳靶向抗病毒药物的普来可那立类似物的构效关系研究
bioRxiv. 2025 Aug 12:2025.08.08.668114. doi: 10.1101/2025.08.08.668114.
2
Respiratory infection with Enterovirus D68 induces severe acute lung inflammation in the pediatric ferret model.肠道病毒D68引起的呼吸道感染在幼雪貂模型中诱发严重的急性肺部炎症。
iScience. 2025 Jul 5;28(8):113071. doi: 10.1016/j.isci.2025.113071. eCollection 2025 Aug 15.
3
Enterovirus Meningitis.肠道病毒脑膜炎
Methods Mol Biol. 2025;2950:107-117. doi: 10.1007/978-1-0716-4674-8_8.
4
A rationally designed 2C inhibitor prevents enterovirus D68-infected mice from developing paralysis.一种经过合理设计的2C抑制剂可防止感染肠道病毒D68的小鼠出现麻痹症状。
Nat Commun. 2025 Jul 1;16(1):5987. doi: 10.1038/s41467-025-61083-8.
5
Coxsackievirus B regulates host circAKAP10 expression to promote viral replication.柯萨奇病毒B调节宿主circAKAP10的表达以促进病毒复制。
Arch Virol. 2025 Jun 27;170(8):166. doi: 10.1007/s00705-025-06348-9.
6
Advances in the Treatment of Enterovirus-D68 and Rhinovirus Respiratory Infections.肠道病毒D68和鼻病毒呼吸道感染的治疗进展
Infect Dis Rep. 2025 Jun 1;17(3):61. doi: 10.3390/idr17030061.
7
Design of a Fluorescence Polarization Probe for Enterovirus 2C Proteins.肠道病毒2C蛋白荧光偏振探针的设计
J Med Chem. 2025 Jul 10;68(13):14041-14053. doi: 10.1021/acs.jmedchem.5c01219. Epub 2025 Jun 21.
8
EV-D68 cleaves LARP1 and PABPC1 by 3Cpro to redirect host mRNA translation machinery toward its genomic RNA.肠道病毒D68型通过3C蛋白酶切割LARP1和PABPC1，将宿主mRNA翻译机制导向其基因组RNA。
PLoS Pathog. 2025 Apr 28;21(4):e1013098. doi: 10.1371/journal.ppat.1013098. eCollection 2025 Apr.
9
Computational discovery of natural inhibitors targeting enterovirus D68 3C protease using molecular docking pharmacokinetics and dynamics simulations.利用分子对接、药代动力学和动力学模拟对靶向肠道病毒D68 3C蛋白酶的天然抑制剂进行计算发现。
Sci Rep. 2025 Mar 31;15(1):11015. doi: 10.1038/s41598-025-95163-y.
10
Caspase-8 activation regulates enterovirus D68 infection-induced inflammatory response and cell death.半胱天冬酶-8激活调节肠道病毒D68感染诱导的炎症反应和细胞死亡。
Biosaf Health. 2024 Mar 7;6(3):171-177. doi: 10.1016/j.bsheal.2024.03.003. eCollection 2024 Jun.
本文引用的文献
1
The Pyrimidine Analog FNC Potently Inhibits the Replication of Multiple Enteroviruses.嘧啶类似物 FNC 能有效抑制多种肠道病毒的复制。
J Virol. 2020 Apr 16;94(9). doi: 10.1128/JVI.00204-20.
2
α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment.α-酮酰胺作为冠状病毒和肠病毒复制的广谱抑制剂：基于结构的设计、合成和活性评估。
J Med Chem. 2020 May 14;63(9):4562-4578. doi: 10.1021/acs.jmedchem.9b01828. Epub 2020 Feb 24.
3
Design, Synthesis, and Evaluation of Novel Enterovirus 71 Inhibitors as Therapeutic Drug Leads for the Treatment of Human Hand, Foot, and Mouth Disease.新型肠道病毒 71 抑制剂的设计、合成与评价及其作为治疗手足口病的治疗药物先导的研究
J Med Chem. 2020 Feb 13;63(3):1233-1244. doi: 10.1021/acs.jmedchem.9b01414. Epub 2020 Jan 29.
4
100 Years of Suramin.苏拉明百年史
Antimicrob Agents Chemother. 2020 Feb 21;64(3). doi: 10.1128/AAC.01168-19.
5
Emetine protects mice from enterovirus infection by inhibiting viral translation.依米丁通过抑制病毒翻译来保护小鼠免受肠道病毒感染。
Antiviral Res. 2020 Jan;173:104650. doi: 10.1016/j.antiviral.2019.104650. Epub 2019 Nov 14.
6
Neurotropism of Enterovirus D68 Isolates Is Independent of Sialic Acid and Is Not a Recently Acquired Phenotype.肠道病毒 D68 分离株的神经嗜性独立于唾液酸，并且不是新近获得的表型。
mBio. 2019 Oct 22;10(5):e02370-19. doi: 10.1128/mBio.02370-19.
7
Pan-viral serology implicates enteroviruses in acute flaccid myelitis.泛病毒血清学提示肠道病毒与急性弛缓性脊髓炎有关。
Nat Med. 2019 Nov;25(11):1748-1752. doi: 10.1038/s41591-019-0613-1. Epub 2019 Oct 21.
8
A Novel Capsid Binding Inhibitor Displays Potent Antiviral Activity against Enterovirus D68.一种新型衣壳结合抑制剂对肠道病毒D68显示出强大的抗病毒活性。
ACS Infect Dis. 2019 Nov 8;5(11):1952-1962. doi: 10.1021/acsinfecdis.9b00284. Epub 2019 Sep 18.
9
Enterovirus pathogenesis requires the host methyltransferase SETD3.肠道病毒发病机制需要宿主甲基转移酶 SETD3。
Nat Microbiol. 2019 Dec;4(12):2523-2537. doi: 10.1038/s41564-019-0551-1. Epub 2019 Sep 16.
10
Understanding Enterovirus D68-Induced Neurologic Disease: A Basic Science Review.了解肠道病毒 D68 引起的神经疾病：基础科学综述。
Viruses. 2019 Sep 4;11(9):821. doi: 10.3390/v11090821.
Zotero 插件